» Articles » PMID: 39981812

A Machine Learning Approach to Build and Evaluate a Molecular Prognostic Model for Endometrial Cancer Based on Tumour Microenvironment

Overview
Journal J Cell Mol Med
Date 2025 Feb 21
PMID 39981812
Authors
Affiliations
Soon will be listed here.
Abstract

Endometrial cancer (EC) incidence and the associated tumour burden have increased globally. To build a molecular expression prognostic model based on the tumour microenvironment to guide personalised treatment using a machine learning approach. Two datasets were reviewed, including a training cohort (n = 698) and a testing cohort (n = 151). All patients underwent hysterectomy ± adnexectomy ± lymph nodes dissection between December 2014 and June 2020 at the PLA General Hospital First Medical Center and received necessary and regular follow-up. We developed novel models using R software to predict factors that affect survival, such as progression-free survival and overall survival. Then, the model was optimised by evaluating the prediction efficiency in multiple dimensions. Eight hundred and forty-nine patients with EC were included in the study. Survival-related influences on EC patients were identified by univariate analysis and cox regression equations. In addition, a nomogram was visualised in conjunction with demographic characteristics and the above meaningful clinicopathological variables. Ultimately, through a comprehensive assessment, a random forest model (RF16) was developed for complementing the findings of the molecular classification of EC. The RF16 not only specifically characterises tumour molecules, but also enhances the generalizability of the model by replacing gene sequencing with immunohistochemistry. This study showed that the machine learning model (RF16) is low-cost, efficient, and clinically valuable in guiding treatment for EC patients.

References
1.
Eakin C, Lai T, Cohen J . Alarming trends and disparities in high-risk endometrial cancer. Curr Opin Obstet Gynecol. 2022; 35(1):15-20. PMC: 9812879. DOI: 10.1097/GCO.0000000000000832. View

2.
Amemiya K, Hirotsu Y, Nagakubo Y, Watanabe S, Amemiya S, Mochizuki H . Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next-generation sequencing. Cancer Med. 2022; 11(23):4479-4490. PMC: 9741978. DOI: 10.1002/cam4.4832. View

3.
Orellana T, Kim H, Beriwal S, Taylor S, Smith K, Lesnock J . Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer. Gynecol Oncol. 2023; 173:81-87. PMC: 11225569. DOI: 10.1016/j.ygyno.2023.04.010. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Oaknin A, Bosse T, Creutzberg C, Giornelli G, Harter P, Joly F . Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(9):860-877. DOI: 10.1016/j.annonc.2022.05.009. View